Pioneered exactly 20 years ago, yeast surface display (YSD) continues to take a major role
in protein engineering among the high-throughput display methodologies that have been …

As a non-antibody scaffold, monobodies based on the fibronectin type III (FN3) domain
overcome antibody size and complexity while maintaining analogous binding loops …

Autoantibodies that recognize extracellular proteins (the exoproteome) exert potent
biological effects but are challenging to detect. Here, we developed rapid extracellular …

Molecular ON-switches in which a chemical compound induces protein–protein interactions
can allow cellular function to be controlled with small molecules. ON-switches based on …

The formulations of peptide-based antitumour vaccines being tested in clinical studies are
generally associated with weak potency. Here, we show that pharmacokinetically tuning the …

Yeast surface display is a powerful technology for engineering a broad range of protein
scaffolds. This protocol describes the process for de novo isolation of protein binders from …

The concept of biomaterials has evolved from one of inert mechanical supports with a long‐
term, biologically inactive role in the body into complex matrices that exhibit selective cell …

The review outlines progress and problems in the design of non-natural antibodies for
clinical applications over the past $10 {-} 15\{\text {years}} $. The modular structure of natural …

Determining the equilibrium-binding affinity (K d) of two interacting proteins is essential not
only for the biochemical study of protein signaling and function but also for the engineering …

Biotherapeutics are attractive anti‐cancer agents due to their high specificity and limited
toxicity compared to conventional small molecules. Antibodies are widely used in cancer …